West Pharmaceutical Servs Analyst Price Targets

Wall Street analyst price targets and consensus rating for West Pharmaceutical Servs (WST).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$399Upside to Avg. PT+8.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$400→$440
Sep 22, 2026	Morgan Stanley	Kallum Titchmarsh	Upgrade	Equal-Weight→Overweight	$365→$400
Sep 9, 2026	UBS	Doug Schenkel	PT Raise	Buy	$340→$415
Aug 3, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$400→$412
Jul 27, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$410→$425
Jul 13, 2026	BNP Paribas	Curtis Moiles	Initiate	Outperform	$447
Jul 9, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$325→$365
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$390→$410
Jul 2, 2026	Keybanc	Paul Knight	PT Raise	Overweight	$350→$390
Jun 9, 2026	Barclays	Luke Sergott	Upgrade	Equal-Weight→Overweight	$310→$400
Jun 2, 2026	Stephens & Co.	Steven Etoch	Maintained	Overweight	$360
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	—
May 29, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$315→$325
Apr 27, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$275→$310
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$265→$275
Feb 13, 2026	Barclays	Luke Sergott	PT Cut	Equal-Weight	$325→$265
Feb 3, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$390→$320
Dec 2, 2025	Morgan Stanley	Kallum Titchmarsh	Initiate	Equal-Weight	$285
Oct 29, 2025	TD Cowen	Brendan Smith	Initiate	Buy	$350
Oct 27, 2025	Barclays	Luke Sergott	PT Raise	Equal-Weight	$275→$325

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.

Benzinga Newsdesk

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

Benzinga Newsdesk

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.

Benzinga Newsdesk

PRO
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

Citigroup analyst Joanne Wuensch maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the price target from $410 to $425.

Benzinga Newsdesk

West Pharmaceutical Services Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

PRO
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

People Also Watch

People Also Watch

West Pharmaceutical Services Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PROLive On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PROMorgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

PROUBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

PROCitigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

PROEvercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

PRO
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415

PRO
Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412

PRO
Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425